



Welcome to the Webinette!
January 10, 2017

Information on how to obtain your no-cost .5 NAADAC contact hour provided at conclusion of this live webinar.



toolsfortreatment

Family-Centered Behavioral Health Support
for Pregnant & Postpartum Women

ATTC | Center of Excellence

www.attcppwtools.org

ATTC Center of Excellence on Behavioral Health for Pregnant and Postpartum Women and Their Families

www.attcppwtools.org

ATTC Regional Center Partners:

Great Lakes ATTC
Mid-America ATTC
New England ATTC
Southeast ATTC

Purpose:

The Center was established to develop a family-centered national curricula, web-based toolkit, and provide support for national training and resource dissemination.

toolsfortreatment

Family-Centered Behavioral Health Support
for Pregnant & Postpartum Women

Substance Abuse and Mental Health Services Administration
SAMHSA
www.samhsa.gov • 1-877-SAMHSA-7 (1-877-726-4727)

Pregnant & Post-Partum Women With Co-Occurring Disorders: Implications for Treatment Providers

Tiffany Cooke, MD, MPH, FAPA

Innovations Behavioral Health, LLC

CoE PPW Webinette #7

January 10, 2017

toolsfortreatment

Family-Centered Behavioral Health Support
for Pregnant & Postpartum Women



Webinette Overview

- COD's occur frequently & can impact mother & child
- There are multifactorial risk factors
- Repeat screening, appropriate referral, & coordinated treatment are key
- Safety profile of meds for mother & fetus must be considered along with appropriate therapy measures




SIGNIFICANCE

toolsfortreatment

Family-Centered Behavioral Health Support
for Pregnant & Postpartum Women

Co-occurring Disorders Defined


- Previously referred to as dual diagnosis
- SAMHSA: coexistence of both a mental health d/o and a SUD





How Many Affected?

Figure 46. Past Year Substance Use Disorder (SUD) and Mental Illness among Adults Aged 18 or Older: 2015



Reprinted from: Center for Behavioral Health Statistics and Quality. (2016). Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51). Retrieved from <http://www.samhsa.gov/data/>




Impact

- Persons w/MH d/o's more likely than those without to have SUD's
- Co-occurrence complicates severity & treatment of each individual disorder
- One condition can exacerbate the other



Impact

- Symptoms often overlap
- Often only 1 of the 2 disorders are treated, sometimes neither
- Untreated/undertreated disorders → ↑homelessness, dysfunctional relationships, incarceration, mortality





Unique issues for women

- Unique risk: higher prevalence of anxiety, MDD in women
- Psych disorders & SUD during pregnancy → adverse outcomes for mothers & offspring
- PPW with psych d/o less likely to report good overall health





Unique issues for women (cont.).

- Most women with a current psych d/o did not receive any mental health care in the preceding 12 mo. regardless of pregnancy status
- Lifetime & past-yr. treatment rates for psych d/o significantly lower for past-year pregnant than non-pregnant women w/psych d/o



Common Co-Morbidities

- MDD
- Anxiety disorders
- PTSD
- Bipolar
- Eating disorders



Prevalence of Psych Disorders

Table 1. Estimated Prevalence of Selected Psychiatric Illness During Pregnancy

Disorder	Illness	Estimated prevalence (%)	Ref.
Depressive disorders	Major depression	13-20	[10,87]
	Bipolar disorder	Unknown	
Anxiety disorders	General anxiety disorder	8.5	[25,28]
	Panic disorder	1-2	
	Post-traumatic stress disorder	3.5	
	Obsessive-compulsive disorder	0.2-1.2	
Eating disorders	Anorexia only	1.4	[43]
	Bulimia only	1.6	
	Both anorexia and bulimia	0.7	
Personality disorders		6.4	
Psychotic disorders		Unknown	[35]

Condition	Fetal Effect	Maternal Effect
MDD	PTD, LBW, miscarriage	Bleeding during pregnancy, miscarriage, higher uterine artery resistance
Bipolar	More research needed, placental abnormalities	Antepartum hemorrhage, placental abnormalities, ↑ chance of risky behavior, higher SUD risk
Panic Disorder	Polyhydramnios, premature L& D	
PTSD	PTD	Ectopic pregnancy, miscarriage, hyperemesis, higher SUD risk
Schizophrenia/ schizoaffective	PTD, LBW, placental abnormalities, cardiac defects	↓rate of live births, ↑ rate of losing pregnancy, ↑ rates of gestational DM, SUD's, seeking less medical care (psych & prenatal)
Eating d/O	Miscarriage, PTD, LBW	Gestational DM, hyperemesis gravidum

PTD:preterm delivery; LBW: low birth weight; L&D: labor & delivery



UNDERSTANDING CO-MORBIDITY

toolsfortreatment

Family-focused Behavioral Health Support
for Pregnant & Postpartum Women

Why the Co-Morbidity?



Self- Medicating:

- Depression leading to drinking to cope with mood
- Bipolar disorder leading to cocaine use to mimic pleasurable manic state, avoid "crash" into depression
- Schizophrenia leading to marijuana use to silence AH



Why the Co-Morbidity? (cont.)


Kindling

- Drugs sensitize neurons
- Leads to more frequent and intense drug use
- MH disorders similarly become more symptomatic, shorter periods between episodes



Why the Co-Morbidity? (cont.)

Genetics

- 
- Families w/ SUD's more likely to have members with mood d/o & vice versa
 - Genes may cause brain to respond to initial drug exposures in ways that promote chronic use → drugs lead to changes causing MH disorders



Other Risk Factors

- Age
- Marital status
- Health status
- Stressful life events
- History of traumatic experiences



DIAGNOSIS & TREATMENT

toolsfortreatment

Family-focused Behavioral Health Support
for Pregnant & Postpartum Women



How do I Identify

- Screen, screen, screen
 - during initial intake
 - again throughout the program
 - end of program
- Woman's self ID



Screening Tools

General: SCL-90

Depression: Edinburgh Postnatal Depression Scale (postpartum) (EPDS)*, Postpartum Depression Screening Scale (PDSS), PHQ-9, BDI, HAM-D

Anxiety: GAD-7, BAI, HAM-A

Bipolar disorder: MDQ



SBIRT


Screening: assess for disorder

Brief **Inter**vention**: HCP engages person to understand & ↓ risks**

Referral to **Treatment**: Refers if additional services are needed

SBIRT Step by Step

4 Phases of SBIRT



Source: Indiana SBIRT



Brief Intervention

- Normalize MH treatment as part of the recovery process
- Destigmatize
- Engage woman as a partner in her recovery



Refer to Treatment

- Screening ≠ diagnosis
- Lack of disorder ≠ lack of symptoms
- Consider referral even if sx & no positive screen
- Engage psychiatry, therapist, ob/gyn, pediatrician



Treatment Goals

- Specialized, integrated care
- ↓ substance use in mother & exposure for child
- ↓ health risks (physical & mental) & sx for mother & child





Treatment Goals (cont.)

- Improving sleep habits
- Improving communication & parenting skills
- Improving nutritional & eating behaviors
- Working on family relationships



Treatment Approaches

- Provide support, linkage to care
- Incorporate non-pharmacologic tx: therapy
- Risk /benefit of medicine vs risk /benefit of untreated psych condition
- Support groups: double trouble
- Avoid punitive tone



MEDICINES

toolsfortreatment

Family-focused Behavioral Health Support
for Pregnant & Postpartum Women






SSRI's

Depression, anxiety, PTSD

Fluoxetine: heart & skull defects

Paroxetine: brain, skull, heart, abdomen


Distribution of specific SSRIs used among women whose baby did not have a birth defect



Source: Key Findings—A Closer Look at the Link Between Specific SSRIs and Birth Defects
<https://www.cdc.gov/pregnancy/meds/treatingfortwo/features/ssrisandbirthdefects.html>



Antipsychotics



Source:Robakis, T, Williams K. Atypical Antipsychotics during Pregnancy (2013). Current Psychiatry. 12(7), 12-18

Generally Avoided in PPW's



- Benzodiazepines
- Valproic acid
- Lithium
- Carbamazepine



Resource

Practice Guidelines: ACOG Guidelines on Psychiatric Medication Use During Pregnancy and Lactation - American Family Physician

View/Print Table

Table 1
Safety of Psychiatric Medications During Pregnancy and Lactation

DRUG	FDA PREGNANCY CATEGORY*	AAP RATING	LACTATION RISK CATEGORY†
Anxiolytics and hypnotics			
Benzodiazepines			
Alprazolam (Xanax)	D	Unknown, of concern	L3
Chlordiazepoxide (Librium)	D	NA	L3
Clonazepam (Klonopin)	D	NA	L3
Clorazepate (Tranxene)	D	NA	L3
Diazepam (Valium)	D	Unknown, of concern	L3; L4 if used chronically
Estazolam (Prosom)‡	X	NA	L3
Flurazepam (Dalmane)	X	NA	L3

<http://www.aafp.org/afp/2008/0915/p772.html>

Tiffany Cooke, MD, MPH, FAPA

Innovations Behavioral Health, LLC

1 Glenlake Pkwy, #700

Sandy Springs, GA 30328

678-448-4688

drcooke@innovationsbh.com



CoE PPW Webinette #7
January 10, 2017

To access recorded webinette:
www.attcppwtools.org

toolsfortreatment

Family-Centered Behavioral Health Support
for Pregnant & Postpartum Women

References

Armstrong, C. (2008). ACOG guidelines on psychiatric medication use during pregnancy and lactation.

Benningfield, M. M., Arria, A. M., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., ... & Martin, P. R. (2010). Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. *The American Journal on Addictions, 19*(5), 416-421.

Center for Behavioral Health Statistics and Quality. (2016). Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51). Retrieved from <http://www.samhsa.gov/data/>

Co-Occurring Disorders Treatment Guide. (n.d.). Retrieved January 02, 2017, from <http://americanaddictioncenters.org/co-occurring-disorders/>

Gold, K. J., & Marcus, S. M. (2008). Effect of maternal mental illness on pregnancy outcomes. *Expert Review of Obstetrics & Gynecology, 3*(3), 391-401.

Key Findings—A Closer Look at the Link Between Specific SSRIs and Birth Defects. (2015). Retrieved January 02, 2017, from <https://www.cdc.gov/pregnancy/meds/treatingfortwo/features/ssrisandbirthdefects.html>

Mericle AA, Ta VM, Holck P, Arria AM. Prevalence, Patterns, and Correlates of Co-Occurring Substance Use and Mental Disorders in the US: Variations by Race/Ethnicity.(2012) *Comprehensive Psychiatry. 53*(6):657-665. doi:10.1016/j.comppsy.2011.10.002.

Najavits, L. M., Weiss, R. D., & Shaw, S. R. (1997). The link between substance abuse and posttraumatic stress disorder in women. *The American journal on addictions, 6*(4), 273-283.

Quello SB, Brady KT, Sonne SC. (2005) Mood Disorders and Substance Use Disorder: A Complex Comorbidity. *Science & Practice Perspectives,3*(1):13-21.

Robakis, T, Williams K. Atypical Antipsychotics during Pregnancy (2013). *Current Psychiatry. 12*(7), 12-18.

Vesga-Lopez, O., Blanco, C., Keyes, K., Olfson, M., Grant, B. F., & Hasin, D. S. (2008). Psychiatric disorders in pregnant and postpartum women in the United States. *Archives of general psychiatry, 65*(7), 805-815.